Micro Clear Secures RMB 100 Million in New Funding; Bloomage BioTechnology Launches AI-Focused Investment Arm; 11 Cosmetic Products Fail Quality Inspection

Apr 02, 2024 17:34 CST Updated 17:34

Microclear Medical

Provider of Medical Imaging and Ophthalmic Diagnosis and Treatment Equipment

Bloomage Biotech

Developer of bioactive substance products, producer of hyaluronic acid raw materials

Industry Trends

丨Microclear Medical Completes New Round of Financing Worth 100 Million Yuan

Microclear Medical is a research and production enterprise specializing in high-end ophthalmic imaging and intelligent equipment. The company focuses on the research, production, and sales of high-end ophthalmic imaging and intelligent equipment.Microclear Medical focuses on the ophthalmology and optometry segments, leveraging its proprietary core hardware devices and integrating artificial intelligence and connectivity technologies to provide high-quality ophthalmic and optometric equipment and services for hospitals and grassroots medical institutions in China.Recently, Microclear Medical announced the completion of a 100 million yuan equity financing round, invested by China's State-owned Capital Venture Investment Fund. This funding will help the company solidify the global position of its core product, the "Ultra-Widefield Confocal Laser Camera," and accelerate new product R&D iterations, market promotion, and the development of a high-caliber talent team.

丨Bloomage Biotech Investment Management Consulting Company Includes AI-Related Business

Qichacha APP shows that recently, Beijing Xirongxin Management Consulting Co., Ltd. was established, with Sun Jingjun as the legal representative, a registered capital of 1 million yuan, and a business scope including:Enterprise Management Consulting;Enterprise Management;Corporate Image Planning;Consulting and planning services;Artificial Intelligence Basic Software Development;Software Sales;Development of artificial intelligence application software, etc.

Qichacha's equity penetration shows that the company is wholly owned by Bloomage Biotech.

Industry Regulation

丨Another 11 batches of cosmetics failed quality inspection

March 29On [date], the Shaanxi Provincial Drug Administration released the Shaanxi Province Cosmetic Quality Announcement (Issue 2024-1, Total Issue 6).To further strengthen the quality supervision of cosmetics and effectively ensure public safety in cosmetic use, 11 batches of products that do not meet standard regulations are hereby announced, including Shengdilun Hair Dye Cream produced by Guangdong Runzhuang Biotechnology Co., Ltd. and L'Oréal Revitalift Hyaluronic Acid Fresh-Pressed Ampoule Mask produced by Suzhou L’Oréal International Cosmetics Co., Ltd.It is reported that the majority of non-conforming items were related to labeling issues and excessive total bacterial count, with four labeled manufacturers denying production.Regarding the substandard cosmetics found in the supervisory sampling inspections, the Shaanxi Provincial Drug Administration has required the relevant local drug regulatory authorities to handle the non-compliant cosmetics production and business units according to law.